You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Carbidopa, an iron chelator and an ABCG2 inducer, for treatment of gouty arthritis

    SBC: South Plains Biotechnology, Inc            Topic: NIAMS

    Our goal is to evaluate the efficacy of the FDA approved drug Carbidopa for the treatment of gouty arthritis in mouse modelsCarbidopa is used to treat Parkinson s diseasebut always in combination of L DOPAnever alone by itselfGouty arthritis is caused by deposition of monosodium urateMSUcrystals in jointsinitiating inflammation and arthritisInterestinglygout is not always directly related to incre ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Continuous real-time fentanyl sensor platform based on smart hydrogels for application in anesthesia

    SBC: SENTIOMED, INC.            Topic: 300

    PROJECT SUMMARY ABSTRACT The opioid fentanyl is administered in millions of procedural sedations every yearIt is very potenthas large interpatient pharmacokinetic variabilityand routinely causes significant respiratory depression if bolused or not titrated judiciouslyDosing and timingcritical for safety and efficacyare presently only possible based on educated guesses and vital signsSedation assoc ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy

    SBC: RIDGELINE THERAPEUTICS LLC            Topic: NIAMS

    Progressive muscle weakness and degeneration is a hallmark of Duchenne muscular dystrophyDMDIn DMD patientsthe lack of dystrophin reduces muscle fiber structural integritymaking muscles vulnerable to persistent injury and damageRepairing these damaged muscles requires the continual activation of muscle stem cellsmuSCwhich leads to muSC dysfunction and senescenceand ultimately the muscle degenerati ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.

    SBC: Oncoimmune Inc            Topic: 100

    Project Summary AbstractThe recent rapid expansion of genomic data greatly contributes to the understanding of disease development and progressionTo translate these genetic discoveries into clinical applicationswe need to develop therapeutic platforms that can specifically modulate the expression of disease related genes in vivoSmall RNAssuch as microRNAs and siRNAs function in messenger RNA silen ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Oral Enzymatic Management of Phenylketonuria

    SBC: ABRI SCIENCE, LLC            Topic: 300

    PhenylketonuriaPKUis a genetic disorder of metabolism characterized by a pathological elevation of phenylalaninePhein the body stemming from a dysfunctional phenylalanine hydroxylase enzymePAHThe resulting high concentrations of Phexcan result in severe intellectual disabilitybehavioral problemsand neurological deficitse gseizuresStrict control of dietary Phe is the primary treatment for PKU curre ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Granulocyte/Monocyte Precursors to Treat Neutropenia after Cancer Chemotherapy

    SBC: CORD BLOOD PLUS, INC.            Topic: 102

    PROJECT SUMMARY ABSTRACT The objective of this proposal is to move our product forward toward commercialization by improving the quality of life for breast cancer chemotherapy patientsThis will be achieved by the following Specific AimsAimwill optimize differentiation of GMPs and neutrophil lineages in culture in response to G CSFThis will be assessed by flow cytometry to quantify production of ne ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Optimizing Usability of the Orally Rehydrate Children at Home Mobile Application- Optimize ORCAH

    SBC: Data2Care Technologies, LLC            Topic: NICHD

    Project Summary Abstract Acute gastroenteritisAGEinfectious diarrhea is a common condition that is costly in the US and highmortality in developing nationsThe cornerstone of AGE management is oral rehydration therapyORTan evidence based technique that has saved overmillion lives in theyears since its introductionThe problem we aim to address is ORT s underuse in developed countries specifically in ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A microfluidic device for blood analysis in neonates

    SBC: Sersense Inc            Topic: NICHD

    ABSTRACT Premature infants are frequently at risk of infectionjaundice and hypoglycemiaconditions monitored by analysis of blood for c reactive proteinCRPbilirubin and glucose respectivelyTypicallymL of blood is drawn each time an infant is tested with multiple blood draws happening over the course of daysGiven that total blood volume of in premature infants ismLup toof blood volume may be lost du ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Advance Early Detection of Lupus Nephritis with ClearGold

    SBC: CLEARNANO INC            Topic: 400

    SummarySystemic lupus erythematosusSLEor lupus is an autoimmune disease that impacts more thanmillion people worldwideincludingmillion AmericansNearlyof these patients will develop lupus nephritiswhich can cause kidney failureAs a resultits financial burden to individual patient can reach $yearmuch higher than many other diseases because of kidney transplantationAlthough early treatment of lupus n ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government